Shares of IXICO plc (LON:IXI – Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 11.33 and traded as high as GBX 11.64. IXICO shares last traded at GBX 11.64, with a volume of 10,050 shares traded.
IXICO Price Performance
The company has a debt-to-equity ratio of 3.32, a current ratio of 2.85 and a quick ratio of 4.90. The firm has a market capitalization of £10.78 million, a price-to-earnings ratio of -4.99, a PEG ratio of -0.38 and a beta of 0.86. The business’s fifty day simple moving average is GBX 11.33 and its 200 day simple moving average is GBX 11.57.
IXICO (LON:IXI – Get Free Report) last released its quarterly earnings data on Tuesday, December 9th. The company reported GBX (1.85) earnings per share (EPS) for the quarter. IXICO had a negative return on equity of 19.14% and a negative net margin of 31.10%. On average, research analysts forecast that IXICO plc will post -289.3584879 EPS for the current year.
About IXICO
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.
Featured Stories
- Five stocks we like better than IXICO
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Can Any Expenses Be Deducted From Capital Gains Tax?
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Forget AI, This Will Be the Next Big Tech Breakthrough
Receive News & Ratings for IXICO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IXICO and related companies with MarketBeat.com's FREE daily email newsletter.
